Ensysce Biosciences (ENSC) Cash & Equivalents (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Cash & Equivalents for 9 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 23.08% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $4.3 million (up 23.08% YoY), while the FY2025 annual figure was $4.3 million, up 23.08% from the prior year.
• Cash & Equivalents advanced to $4.3 million in Q4 2025 per ENSC's latest filing, from $1.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.3 million in Q4 2021 and bottomed at $250000.0 in Q1 2021.
• Historically, Cash & Equivalents has averaged $4.3 million across 5 years, with a median of $3.5 million in 2024.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 12697.56% — and 2023, when it tumbled 83.23%.
• Ensysce Biosciences' Cash & Equivalents stood at $12.3 million in 2021, then tumbled by 74.34% to $3.1 million in 2022, then plunged by 64.3% to $1.1 million in 2023, then jumped by 211.68% to $3.5 million in 2024, then climbed by 23.08% to $4.3 million in 2025.
• Business Quant data shows ENSC's Cash & Equivalents at $4.3 million in Q4 2025, $1.7 million in Q3 2025, and $2.2 million in Q2 2025.